Navigation Links
Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal

ing new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statements on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

Contact

Calando Pharmaceuticals, Inc.
John Petrovich, 626-305-9322
jpetrovich@calandopharma.com
www.calandopharma.com
or
Arrowhead Research Corporation
Virginia E. Dadey, 212-541-3707
vdadeyvdadey@arrowres.com
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Calando Pharmaceuticals Announces Preclinical Efficacy and Safety Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting
2. Arrowhead Subsidiaries Insert & Calando Present Data on Cyclosert Drug Delivery System at AACR Meeting
3. Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
4. Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
5. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
11. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:12/1/2008)... Md., Dec. 1 Vanda Pharm...ion in The Lancet , one of the world,s leading me...novel circadian regulator, experimental compound t...am et al(1) is entitled "Melatonin agonist tasimel...time shift: two randomised controlled multicentre ...
(Date:12/1/2008)...tudy shows the Prox1 gene is a two-way switch that...s to be reprogrammed so that they lose their ident..., , MEMPHIS, Tenn., Dec. 1 /PRNewswire-USNew...rch Hospital have discovered that a certain differ...ity that it requires the constant expression of a ...
(Date:12/1/2008)...ec. 1 GeoVax Labs, Inc.,...echnology company developing,human vaccines for d...rus) and,other infectious agents, announced today...ials will take place in twelve sites across North ...collaboration with The National Institutes of,Hea...
(Date:11/28/2008)...IS, Nov. 28 Eli Lilly an...mental New Drug Application (sNDA) from,the U.S. ... (duloxetine HCl),for the management of chronic p...he first half of 2009, adding data from a recently...is pain of the knee. , The decision does no...
Breaking Medicine Technology:Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Chocolate Milk 3A The Official Drink of Halloween 2863 1Chocolate Milk 3A The Official Drink of Halloween 2863 2Chocolate Milk 3A The Official Drink of Halloween 2863 3Chocolate Milk 3A The Official Drink of Halloween 2863 4Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations 2858 1Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations 2858 2Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations 2858 3Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 1Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 2Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 3Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 4Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 5Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 6Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 1Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 2Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 3Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 4Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 5Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 6
...duces TNF-alpha Production Through Inhibition,of P...ewswire/ -- Anacor,Pharmaceuticals, a privately he...ults from its placebo-controlled Phase 1 trial of,...estigation for,the treatment of psoriasis. The tri...ty comparable to existing topical,treatments for p...
... York, June 06, 2007 /PRNewswire-FirstCall/,-- XTL...as,completed the analysis of results from a Phase ...ronic Hepatitis C. This Phase I,trial was a placeb...hich evaluated the safety, tolerability and antivi...125. The study enrolled 56,patients into seven coh...
Other Medicine Technology:Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory,Compound, Shows Efficacy in Psoriasis 2XTL Provides Update on Phase I Clinical Trial of XTL-2125 2XTL Provides Update on Phase I Clinical Trial of XTL-2125 3
(Date:12/2/2008)...iginal Special Features MLS Stars and Promotes Hea...re/ -- Juniper Content Corporation,s (OTC Bulleti... fastest-growing Spanish-language children,s netwo...al special Juega Como un MLS Pro , the climax of ...ague Soccer, on Sunday, December 7th at 7 PM EST. ...
(Date:12/2/2008)...CKVILLE, Md., Dec. 2 Neu...oday that it has entered into a,collaboration wit...aiwan, to,advance development of Neuralstem,s hum...ollaboration will focus on Amyotrophic Lateral Scl...nn-Zong Lin, MD, PhD as principle,investigator. ,...
(Date:12/2/2008)...LVERN, Pa., Dec. 2 Arlington Medic...intelligence for the pharmaceutical and diagnostic...sen Pharmaceuticals, Levaquin,is the preferred qu...eral,medical-surgical hospitals in the United Sta..., sinus, skin and urinary tract infections caused ...
(Date:12/2/2008)...rcentage of Biologic-Treated Psoriasis Patients Wi...Decision Resources , , WALTHAM, Mass., Dec....world,s leading research and advisory firms for ph...logic agents, particularly Centocor/Janssen-Cilag,...e moderate to severe psoriasis drug market to more...
Breaking Medicine News(10 mins):Health News:Sorpresa! Premieres Juega Como un MLS Pro 2Health News:Neuralstem Collaborates with Hospital in Taiwan to Develop Additional ALS Stem Cell Clinical Trials 2Health News:Levaquin is the Preferred Quinolone Among More Than Half of All General Medical-Surgical Hospitals in the United States 2Health News:Biologic Drugs, Particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai's Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017 2
...alian Medical Association (AMA) has issued a warni...tly trained doctors //in the future due to a lack ...MA president has written to the federal MPs and se... in place that would help to deal with the increas...
... health authorities are reconsidering recent chang...doctors of Indian origin ineligible// to work in t...th (DoH) and the home office had put in place a ne... to prove that no suitable candidate was available...
...me the scarcity of doctors in rural areas, the Goa...assing out of state-run medical colleges// to serv...ratapsingh Rane said. The state cabinet decided ...d to be signed by the medical students to serve in...
...rs have found for the first time that human embryo...coaxed to develop into mature T-cells//, raising h...s from the UCLA AIDS Institute and the Institute f... found that it is possible to convert human embryo...
Other Medicine News:Health News:Britain Reconsidering New Visa Rules for Indian Doctors 2Health News:T-cells Developed from Human Embryonic Stem Cells 2
Bard Coude-Tip Latex Urethral Catheter, Two Eyes (Tiemann Model)
Used for stone manipulation and removal in the urinary tract. Supplied sterile in peel-open packages. Intended for one-time use.
The Coude tip design facilitates negotiation of the prostatic urethra. It is available in a medium length olive Coude tip with a single drainage eye. The red latex construction provides added stiffne
BARDEX Red Rubber Urethral Catheter (Robinson Model)
Medicine Products: